Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  ImmunoCellular Therapeutics Ltd    

IMMUNOCELLULAR THERAPEUTICS LTD
Mes dernières consult.
Most popular
Report
 SummaryNewsCalendarCompanyFinancialsRevisions 
Financials ($)
Sales 2017 2,40 M
EBIT 2017 -26,0 M
Net income 2017 -19,5 M
Debt 2017 -
Yield 2017 -
Sales 2018 4,30 M
EBIT 2018 -8,20 M
Net income 2018 -10,00 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 2,63x
Capi. / Sales2018 1,47x
Capitalization 6,30 M
More Financials
Company
ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers.The company's lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma... 
Sector
Biotechnology & Medical Research
Calendar

- No events available -

More about the company
Latest news on IMMUNOCELLULAR THERAPEUTIC
10/11 IMMUNOCELLULAR THERAPEUTICS, LTD. : Regulation FD Disclosure, Financial Statemen..
10/03 IMMUNOCELLULAR THERAPEUTICS TO PRESE : 00pm ET
09/21 IMMUNOCELLULAR THERAPEUTICS : Announces NYSE MKT Acceptance of its Plan of Compl..
09/19 IMMUNOCELLULAR THERAPEUTICS LTD : ImmunoCellular, Innovative Cellular Platform, ..
09/13 IMMUNOCELLULAR THERAPEUTICS : Announces NYSE MKT Acceptance of its Plan of Compl..
08/31 IMMUNOCELLULAR THERAPEUTICS : Provides Business Update on Research and Developme..
08/28 IMMUNOCELLULAR THERAPEUTICS, LTD. : Other Events, Financial Statements and Exhib..
08/23 IMMUNOCELLULAR THERAPEUTICS : Provides Business Update on Research and Developme..
08/17 IMMUNOCELLULAR THERAPEUTICS, LTD. : Change in Directors or Principal Officers (f..
08/17 IMMUNOCELLULAR THERAPEUTICS, LTD. : Results of Operations and Financial Conditio..
More news
Sector news : Biotechnology & Medical Research - NEC
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval -- Update
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval
10/18DJACTELION : J&J Net Income Falls After Actelion Deal -- WSJ
10/17 Regeneron-Sanofi drug succeeds mid-stage study
10/17DJJOHNSON & JOHNSON : Outlook Buoyed by Drug Unit -- Update
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
2016 ImmunoCellular Therapeutics' (IMUC) CEO Andrew Gengos on Q3 2016 Results - Ea..
2016 ImmunoCellular Therapeutics EPS in-line
2016 ImmunoCellular Therapeutics' (IMUC) CEO Andrew Gengos on Q2 2016 Results - Ea..
2016 ImmunoCellular Therapeutics beats by $0.01
2016 ImmunoCellular's late-stage study of lead product candidate in glioblastoma c..
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 1
Average target price -
Spread / Average Target -100%
EPS Revisions
Managers
NameTitle
Anthony J. Gringeri President, Chief Executive Officer & Director
Gary S. Titus Chairman & Secretary
David E. Fractor Chief Financial & Accounting Officer
Steven J. Swanson Senior Vice President-Research
John S. Yu Director
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOCELLULAR THERAPEUTICS LTD6
INCYTE CORPORATION13.96%24 054
QUINTILES IMS HOLDINGS INC33.89%22 162
LONZA GROUP59.15%19 392
CELLTRION, INC.--.--%19 297
ALNYLAM PHARMACEUTICALS, INC.208.84%10 522